{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=16&q=advanced+solid+tumors",
    "query": {
      "q": "advanced solid tumors",
      "condition": "Cancer",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 5924,
    "total_pages": 593,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=17&q=advanced+solid+tumors&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=15&q=advanced+solid+tumors&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T07:39:20.831Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00347919",
      "title": "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Breast"
      ],
      "interventions": [
        {
          "name": "pazopanib (GW786034) 400 mg",
          "type": "DRUG"
        },
        {
          "name": "lapatinib (GW572016) 1500 mg",
          "type": "DRUG"
        },
        {
          "name": "lapatinib (GW572016) 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "pazopanib (GW786034) 800 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 189,
      "start_date": "2006-07",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-02-25",
      "last_synced_at": "2026-10-14T07:39:20.831Z",
      "location_count": 19,
      "location_summary": "Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00347919"
    },
    {
      "nct_id": "NCT00508807",
      "title": "RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoid Malignancies",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "RTA 402",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2006-04",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-10-14T07:39:20.831Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00508807"
    },
    {
      "nct_id": "NCT07404332",
      "title": "5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Locally Advanced Solid Tumor",
        "Metastatic Tumor"
      ],
      "interventions": [
        {
          "name": "5 Azacytidine",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mohammed Milhem",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 35,
      "start_date": "2026-02-11",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-14T07:39:20.831Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07404332"
    },
    {
      "nct_id": "NCT05945823",
      "title": "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer",
        "Esophageal Adenocarcinoma",
        "Esophageal Squamous Cell Cancer",
        "Siewert Type 1 GEJ Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Futibatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Levoleucovorin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2023-07-13",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-14T07:39:20.831Z",
      "location_count": 16,
      "location_summary": "Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05945823"
    },
    {
      "nct_id": "NCT06031441",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Solid Tumors",
        "Recurrent Solid Tumors",
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "RO7566802",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2023-11-27",
      "completion_date": "2027-03-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-14T07:39:20.831Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Harrisburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06031441"
    },
    {
      "nct_id": "NCT01823679",
      "title": "Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Skin",
        "Recurrent Skin Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2013-03",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2018-04-12",
      "last_synced_at": "2026-10-14T07:39:20.831Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01823679"
    },
    {
      "nct_id": "NCT03547973",
      "title": "Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab Govitecan-hziy",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 502,
      "start_date": "2018-08-13",
      "completion_date": "2030-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-14T07:39:20.831Z",
      "location_count": 30,
      "location_summary": "Tucson, Arizona • San Francisco, California • Littleton, Colorado + 25 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03547973"
    },
    {
      "nct_id": "NCT06074705",
      "title": "A Study of DS-1471a In Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "DS-1471a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2023-08-04",
      "completion_date": "2025-07-29",
      "has_results": false,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-10-14T07:39:20.831Z",
      "location_count": 2,
      "location_summary": "Sarasota, Florida • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06074705"
    },
    {
      "nct_id": "NCT03849469",
      "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Cervical Carcinoma",
        "Pancreatic Carcinoma",
        "Triple Negative Breast Cancer",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Nasopharyngeal Carcinoma",
        "Renal Cell Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Small Cell Lung Carcinoma",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Advanced or Metastatic Solid Tumors",
        "Prostate Carcinoma",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Squamous Cell Anal Cancer",
        "Squamous Cell Penile Carcinoma",
        "Squamous Cell Vulvar Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "XmAb®22841",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab (Keytruda®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-05-29",
      "completion_date": "2023-02-16",
      "has_results": false,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-10-14T07:39:20.831Z",
      "location_count": 28,
      "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03849469"
    },
    {
      "nct_id": "NCT00323869",
      "title": "Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2006-06",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2016-09-07",
      "last_synced_at": "2026-10-14T07:39:20.831Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • San Jose, California • Stanford, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323869"
    }
  ]
}